Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

GLP-1 receptor agonists like Ozempic and Wegovy have a lot of scientific data to support their use—and they can help people ...

Learn how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

GLP-1R agonist use is associated with a decrease in IOP, although this correlation is not statistically significant.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients on GLP-1 receptor agonists had a low risk of food retention when an esophagogastroduodenoscopy (EGD ...

GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...

A study highlights that GLP-1 RAs are linked to a reduced risk of cirrhosis in patients with MASLD and diabetes. Learn more ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Kourtney Kardashian’s vitamin and supplement brand Lemme launched GLP-1 daily capsules in mid-September. For $90 a month, the product promises — with an asterisk — to curb cravings, manage ...

Last week, Vermont Senator Bernie Sanders pressed the chief executive officer of Novo Nordisk to lower prices of popular weight-loss drugs such as semaglutide – marketed in the United States as ...